Clinical Trials Update: July 14, 2005
Thyroid Cancer Hot Flash Multiple Sclerosis
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
The purpose of the study is to determine if AMG 706 will have clinically meaningful anti-tumor activity in people with locally advanced or metastatic thyroid cancer who are not candidates for radioactive iodine therapy or local therapies. Participants must be at least 18, have histologically confirmed locally advanced or metastatic thyroid cancer, measurable disease, normal blood pressure (if history of hypertension, blood pressure must be controlled with medication), evidence of disease progression within 6 months before starting study, and not a candidate for surgical resection, external beam radiotherapy, radioiodine therapy, or other local therapy. Research sites located throughout the United States.
If you experience at least three moderate to severe hot flashes per day for at least seven days, you may qualify to participate in this clinical research study. Qualified participants will receive all study related care, including doctor visits, physical exams, investigational medication, and lab services at no cost. Participants may be compensated for time and travel. Research site located in Lawrenceville, NJ.
This clinical research study will test an experimental therapy designed to suppress the inflammation that causes damage to nerve fibers in patients with MS. The study drug is delivered by injection administered by a research nurse once a week for the first month and then once a month for four months. People with MS who have experienced two or more attacks in the past two years or one or more attacks in the past six months may qualify. Must also be between 18-65 and not currently taking disease modifying therapy (including beta interferons or glatiramer acetate). Research site located in Henderson, Nev.
Copyright 2005 CenterWatch. All rights reserved.